参考文献/References:
[1] Adamczak DM,Oko-Sarnowska Z. Sudden cardiac death in hypertrophic cardiomyopathy[J]. Cardiol Rev,2018,26(3):145-151.
[2] Maron BJ,Gardin JM,Flack JM,et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults[J]. Circulation,1995,92(4):785-789.
[3] Burke MA,Cook SA,Seidman JG,et al. Clinical and mechanistic insights into the?genetics of cardiomyopathy[J]. J Am Coll Cardiol,2016,68(25):2871-2886.
[4] Andersen PS,Havndrup O,Hougs L,et al. Diagnostic yield,interpretation,and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives[J]. Hum Mutat,2009,30(3):363-370.
[5] Marsiglia JD,Pereira AC. Hypertrophic cardiomyopathy:how do mutations lead to disease?[J]. Arq Bras Cardiol,2014,102(3):295-304.
[6] Nag S,Trivedi DV,Sarkar SS,et al. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations[J]. Nat Struct Mol Biol,2017,24(6):525-533.
[7] Kensler RW,Shaffer JF,Harris SP. Binding of the N-terminal fragment C0-C2 of cardiac MyBP-C to cardiac F-actin[J]. J Struct Biol,2011,174(1):44-51.
[8] Behrens-Gawlik V,Mearini G,Gedicke-Hornung C,et al. MYBPC3 in hypertrophic cardiomyopathy:from mutation identification to RNA-based correction[J]. Pflugers Arch,2014,466(2):215-223.
[9] Spudich JA. The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy[J]. Biochem Soc Trans,2015,43(1):64-72.
[10] Carrier L,Schlossarek S,Willis MS,et al. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy[J]. Cardiovasc Res,2010,85(2):330-338.
[11] Green EM,Wakimoto H,Anderson RL,et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science,2016,351(6273):617-621.
[12] Kawas RF,Anderson RL,Ingle S,et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle[J]. J Biol Chem,2017,292(40):16571-16577.
[13] Lee KH,Sulbarán G,Yang S,et al. Interacting-heads motif has been conserved as a mechanism of myosinⅡ inhibition since before the origin of animals[J]. Proc Natl Acad Sci U S A,2018,115(9):E1991-E2000.
[14] Anderson RL,Trivedi DV,Sarkar SS,et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A,2018,115(35):E8143-E8152.
[15] Alamo L,Qi D,Wriggers W,et al. Conserved intramolecular interactions maintain myosin interacting-heads motifs explaining tarantula muscle super-relaxed state structural basis[J]. J Mol Biol,2016,428(6):1142-1164.
[16] Lang R,Gomes AV,Zhao J,et al. Functional analysis of a troponin I(R145G) mutation associated with familial hypertrophic cardiomyopathy[J]. J Biol Chem,2002,277(14):11670-11678.
[17] Moore JR,Leinwand L,Warshaw DM. Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor[J]. Circ Res,2012,111(3):375-385.
[18] Sparrow AJ,Watkins H,Daniels MJ,et al. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations[J]. Am J Physiol Heart Circ Physiol,2020,318(3):H715-H722.
[19] 宋雷,邹玉宝,汪道文,等. 中国成人肥厚型心肌病诊断与治疗指南[J]. 中华心血管病杂志,2017,45(12):1015-1032.
[20] Ho CY,Mealiffe ME,Bach RG,et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2020,75(21):2649-2660.
[21] Heitner SB,Jacoby D,Lester SJ,et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy:a clinical trial[J]. Ann Intern Med,2019,170(11):741-748.
[22] Olivotto I,Oreziak A,Barriales-Villa R,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2020,396(10253):759-769.
[23] Saberi S,Cardim N,Yamani M,et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy:EXPLORER-HCM cardiac magnetic resonance substudy analysis[J]. Circulation,2021,143(6):606-608.
[24] Almeida AG. NT-proBNP and myocardial fibrosis:the invisible link between health and disease[J]. J Am Coll Cardiol,2017,70(25):3110-3112.
[25] Coats CJ,Gallagher MJ,Foley M,et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy[J]. Eur Heart J,2013,34(32):2529-2537.
[26] Cui H,Wu X,Wang S,et al. Time and age dependent decrease of NT-proBNP after septal myectomy in hypertrophic obstructive cardiomyopathy[J]. Clin Chem Lab Med,2017,55(10):1614-1620.
[27] Olivotto I,Tomberli B,Spoladore R,et al. Hypertrophic cardiomyopathy:the need for randomized trials[J]. Glob Cardiol Sci Pract,2013,2013(3):243-248.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(11):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(11):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(11):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(11):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[5]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[6]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[7]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(11):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[8]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(11):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
[9]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(11):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
[10]王蕊 赵鹏军.儿童肥厚型心肌病诊断方法及其对猝死风险评估的价值[J].心血管病学进展,2023,(8):681.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.003]
WANG Rui,ZHAO Pengjun.Diagnostic Methods of Hypertrophic Cardiomyopathy in Children and Its Value in Risk Assessment of Sudden Death[J].Advances in Cardiovascular Diseases,2023,(11):681.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.003]